LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in February:

  • 13th Annual Congress of the European Association for Hemophilia and Allied Disorders (EAHAD), February 5 – 7, The Hague, the Netherlands.

    • uniQure will deliver 7 presentations on the development of its gene therapy candidates etranacogene dezaparvovec for hemophilia B, AMT-180 for hemophilia A, and its technology platform.
    • Further details on the company’s presentations will follow closer to conference. 

  • 16th Annual WORLD Symposium, February 10 – 13, Orlando, FL.

    • Ying Poi Liu, Ph.D., senior scientist at uniQure, will present on the development of an AAV5-based gene therapy for Fabry disease, on Tuesday, February 11, from 4:30 – 6:30 p.m. ET.
     
  • CHDI 15th Annual Huntington’s Therapeutics Conference, February 22 – 25, Palm Springs, CA.

    • uniQure will deliver 5 presentations on the development of AMT-130, the company’s AAV-gene therapy candidate for the treatment of Huntington’s disease.
    • Further details on the company’s presentations will follow closer to the conference.
     
  • 64th Annual Meeting of the Society of Thrombosis and Haemostasis Research – GTH 2020, February 18 – 21, Bremen, Germany.

    • Professor Wolfgang Miesbach, M.D., Ph.D., of the University Hospital Frankfurt in Germany, will present 12-month follow-up data on the company’s gene therapy candidate etranacogene dezaparvovec in hemophilia B, as well as four-year follow-up data on AMT-060, also in patients with hemophilia B.

  • 9th Annual SVB Leerink Global Healthcare Conference, February 25 – 27, New York City.

    • Matt Kapusta, chief executive officer at uniQure, will participate in a fireside chat with research analyst Joseph Schwarz, on Tuesday, February 25, from 2:30 – 2:55 p.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.
    • Members of uniQure’s management team will participate in one-on-one investor meetings throughout the day on Tuesday, February 25.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorEva M. MulderTom Malone
Direct: 339-970-7536Direct: +31 20 240 6103Direct: 339-970-7558